Update on novel agents in renal cell carcinoma

References

• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol.13, 688–696 (1995).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med.335, 865–875 (1996).
   PubMed Web of Science ®Google Scholar
• Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J. Pathol.183, 131–133 (1997).
   PubMed Web of Science ®Google Scholar
• Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer22, 200–209 (1998).
   PubMed Web of Science ®Google Scholar
• Latif F, Tory K, Gnarra J et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science260, 1317–1320 (1993).
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet.7, 85–90 (1994).
   PubMed Web of Science ®Google Scholar
• Gallou C, Joly D, Mejean A et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat.13, 464–475 (1999).
   PubMed Web of Science ®Google Scholar
• Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol.196, 186–193 (2002).
   PubMed Web of Science ®Google Scholar
• Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA91, 9700–9704 (1994).
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J. Clin. Oncol.22, 4991–5004 (2004).
   PubMed Web of Science ®Google Scholar
• Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem.270, 13333–13340 (1995).
   PubMed Web of Science ®Google Scholar
• Maher ER, Kaelin WG Jr. Von Hippel-Lindau disease. Medicine (Baltimore)76, 381–391 (1997).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9, 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Kasid U, Dritschilo A. RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene22, 5876–5884 (2003).
   PubMed Web of Science ®Google Scholar
• Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol.16, 1688–1694 (2005).
   PubMed Web of Science ®Google Scholar
• Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer92, 1855–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res.11, 5472–5480 (2005).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol.23, 965–972 (2005).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol.19, 265–268 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295, 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst.99, 81–83 (2007).
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.26, 5204–5212 (2008).
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet370, 2011–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370, 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26, 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372, 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol.8, 975–984 (2007).
   PubMed Web of Science ®Google Scholar
• Kumar R, Harrington LE, Hopper TM et al. Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. Proceedings of the American Society of Clinical Oncology 23 (2005) (Abstract 9537).
   Google Scholar
• Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a Phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J. Clin. Oncol.26, (2008) (Abstract 5046).
   Google Scholar
• Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol.27, 15s (2009) (Abstract 5021).
   Google Scholar
• Verheul HM, Hammers H, van Erp K et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin. Cancer Res.13, 4201–4208 (2007).
   PubMed Web of Science ®Google Scholar
• Dupont J, Schwartz L, Koutcher J et al. Phase I and pharmacokinetic study of VEGF trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol.22, 3009 (2004).
   Google Scholar
• Bhargava P, Esteves B, Lipatov ON et al. Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC): interim results of a Phase II randomized discontinuation trial. Presented at: 2009 Genitourinary Cancers Symposium Orlando, FL, USA 26–28 Feburary 2009 (Abstract 283).
   Google Scholar
• Eisen T, Joensuu H, Nathan P et al. Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer. J. Clin. Oncol.27, 15s (2009) (Abstract 5033).
   Google Scholar
• Tannir N, Wong Y, Kollmannsberger C et al. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: efficacy and safety results. J. Clin. Oncol.27, 15s (2009) (Abstract 5036).
   Google Scholar
• Qian DZ, Kato Y, Shabbeer S et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res.12, 634–642 (2006).
   PubMed Web of Science ®Google Scholar
• Qian DZ, Wang X, Kachhap SK et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res.64, 6626–6634 (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet.16, 68–73 (1997).
   PubMed Web of Science ®Google Scholar
• Eder JP, Appleman L, Heath E et al. A Phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). J. Clin. Oncol.24(18 Suppl.), 3041 (2006).
   Google Scholar
• Ross RW, Stein M, Sarantopoulos J et al. A Phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC) 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(Suppl. 18), (2007) (Abstract 15601)
   Google Scholar
• Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am. J. Pathol.159, 2271–2280 (2001).
   PubMed Web of Science ®Google Scholar
• Gale NW, Thurston G, Hackett SF et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell3, 411–423 (2002).
   PubMed Web of Science ®Google Scholar
• Currie MJ, Gunningham SP, Turner K et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel–Lindau gene and hypoxia. J. Pathol.198, 502–510 (2002).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.25, 2369–2376 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol.27(27), 4462–4468 (2009).
   PubMed Web of Science ®Google Scholar
• Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol.182, 29–34 (2009).
   PubMed Web of Science ®Google Scholar
• Whorf RC, Hainsworth JD, Spigel DR et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J. Clin. Oncol.26(20 Suppl.), (2008) (Abstract 5010).
   Google Scholar
• Atkins MB, Ernstoff MS, Figlin RA et al. Innovations and challenges in renal cell carcinoma: summary statement from the second Cambridge conference. Clin. Cancer Res.13, 667s–670s (2007).
   Google Scholar
• Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol.26, 3709–3714 (2008).
   PubMed Web of Science ®Google Scholar
• Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 1432–1439 (2009).
   PubMed Web of Science ®Google Scholar